| Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial T Takase, A Nakamura, C Yamamoto, H Nomoto, A Miya, M Dannoura, ... Journal of diabetes investigation 10 (3), 699-705, 2019 | 40 | 2019 |
| The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) N Kitao, H Miyoshi, T Furumoto, K Ono, H Nomoto, A Miya, C Yamamoto, ... Cardiovascular diabetology 16, 1-10, 2017 | 37 | 2017 |
| Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone KY Cho, A Nakamura, K Omori, T Takase, A Miya, K Yamamoto, ... Journal of Diabetes Investigation 12 (7), 1272-1277, 2021 | 30 | 2021 |
| Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a … A Miya, A Nakamura, H Miyoshi, KY Cho, S Nagai, Y Kurihara, S Aoki, ... Journal of diabetes investigation 9 (1), 119-126, 2018 | 29 | 2018 |
| Impact of glucose loading on variations in CD4+ and CD8+ T cells in Japanese participants with or without type 2 diabetes A Miya, A Nakamura, H Miyoshi, Y Takano, Y Terauchi Frontiers in Endocrinology 9, 333841, 2018 | 25 | 2018 |
| Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 … KY Cho, A Nakamura, K Omori, T Takase, A Miya, N Manda, Y Kurihara, ... Diabetes, Obesity and Metabolism 21 (3), 710-714, 2019 | 19 | 2019 |
| Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment A Miya, A Nakamura, T Handa, H Nomoto, H Kameda, KY Cho, S Nagai, ... Journal of diabetes investigation 12 (5), 738-746, 2021 | 16 | 2021 |
| Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring A Miya, A Nakamura, T Handa, H Nomoto, H Kameda, KY Cho, S Nagai, ... Scientific reports 11 (1), 9057, 2021 | 14 | 2021 |
| Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A … Y Takahashi, H Nomoto, H Yokoyama, Y Takano, S Nagai, A Tsuzuki, ... Diabetes, Obesity and Metabolism 25 (6), 1503-1511, 2023 | 11 | 2023 |
| Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A … Y Oe, H Nomoto, A Nakamura, S Kuwabara, Y Takahashi, A Yasui, ... Journal of Diabetes Research 2022, 2022 | 10 | 2022 |
| Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes K Chiba, H Nomoto, A Nakamura, KY Cho, K Yamashita, Y Shibayama, ... Journal of diabetes investigation 12 (2), 176-183, 2021 | 8 | 2021 |
| Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study A Miya, A Nakamura, H Miyoshi, S Ukawa, K Nakamura, T Nakagawa, ... Journal of diabetes investigation 11 (4), 964-970, 2020 | 7 | 2020 |
| The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study T Handa, A Nakamura, A Miya, H Nomoto, H Kameda, KY Cho, S Nagai, ... Diabetology & Metabolic Syndrome 13, 1-8, 2021 | 6 | 2021 |
| Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes K Takahashi, KY Cho, A Nakamura, A Miya, A Miyoshi, C Yamamoto, ... Journal of diabetes investigation 10 (2), 429-438, 2019 | 6 | 2019 |
| Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective … H Nomoto, S Furusawa, A Nakamura, J Takeuchi, S Nagai, H Yokoyama, ... BMJ open 12 (5), e056885, 2022 | 5 | 2022 |
| Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis A Miyoshi, H Kameda, S Nagai, A Nakamura, A Miya, T Takase, T Atsumi, ... Journal of Diabetes Investigation 12 (7), 1293-1300, 2021 | 4 | 2021 |
| Glucose tolerance is improved following surgery for silent somatotroph adenoma A Miya, A Nakamura, H Miyoshi, H Kameda, H Nomoto, S Nagai, Y Omori, ... International Journal of Diabetes and Clinical Research 2 (6), 047, 2015 | 4 | 2015 |
| Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized … S Furusawa, H Nomoto, H Yokoyama, Y Suzuki, A Tsuzuki, K Takahashi, ... Diabetes, Obesity and Metabolism 26 (3), 961-970, 2024 | 3 | 2024 |
| Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study K Kito, H Nomoto, I Sakuma, A Nakamura, KY Cho, H Kameda, A Miya, ... Diabetes Research and Clinical Practice 192, 110091, 2022 | 3 | 2022 |
| Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis Y Takahashi, H Kameda, A Miya, H Nomoto, KY Cho, A Nakamura, ... Pituitary 25 (2), 321-327, 2022 | 3 | 2022 |
